We want to become the undisputed leader in delivering Microbiome Ecosystem Therapies to treat moderate to severe dysbiosis in patients by mastering different modalities.
– Innovate and raise awareness to deliver better care,
– Contribute to employees-growth within a people-oriented ecosystem,
– Place ethics and transparency at the core of the Company’s strategy,
– Control and measure our impact on the environment.
Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.
Engineer, MBA
Carole is the Chief Technology Officer at MaaT Pharma and has led MaaT Pharma’s pharmaceutical development activities since 2014. She brings 20 years of experience in the pharmaceutical industry, having previously held multiple responsibilities in cGMP manufacturing at Biorad and has been in charge of operations for a start-up company specializing in glycosylated proteins. She is the co-author of 7 published patents and 7 scientific publications.
PhD in microbiology, Engineer in Agronomy, Genetics and Biotechnology
Pharm.D., MBA
Eric joined MaaT Pharma in November 2024 as Chief Financial Officer.
Eric is a senior financial executive with extensive experience in the biotech industry with companies listed on Euronext Paris and on the U.S. Nasdaq market. Prior to joining MaaT Pharma, Eric successfully conducted as CFO & COO of Erytech Pharma, a French late-stage drug development company, its Nasdaq IPO and subsequent financial rounds amounting to over EUR 300 million and supervised the scale-up of the company’s operations from a single site based in France to a multi-site company of 240 employees in US and Europe and most recently its strategic merger. Throughout his 30-year career, Eric has developed a solid international experience across a variety of operational settings.
Émilie Plantamura, PharmD, PhD, is Deputy Chief Medical Officer at MaaT Pharma, where she drives the Company’s clinical oncology programs with deep scientific and medical expertise. Since joining MaaT Pharma in 2015, she has played a pivotal role in advancing the Company’s innovative therapies, building on a strong academic foundation in immunology and microbiome research.
Dr. Plantamura holds a Doctorate in Pharmacy and a PhD in Immunology, with research centered on the interplay between the gut microbiota and the immune system in models of sterile inflammation. She also earned a specialized University Diploma in allogeneic hematopoietic stem cell transplantation from Sorbonne University, further underscoring her expertise in complex therapeutic areas.
Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at MaaT Pharma. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson’s Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company’s scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of Xervyteg® in aGvHD.
Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.
Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.
Engineering degree Ecole Centrale Paris, MBA from Insead
PharmD, PhD
Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle, has been appointed in June 2023 as independent director and Chair of the ESG committee. Nadia brings a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.
Doctorate in immuno-analysis and innovation in clinical biology – Sanofi Diagnostics Pasteur / CNRS.
Master’s degree in Business Administration from IAE Poitiers.
Artificial Intelligence in Health University Diploma at Université Paris Cité.
Chief Corporate and People Operations Officer
Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan.
Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l’Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.
CFO
Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.
Engineering degree from Ecole Centrale Paris
Dr. Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD.
With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.
Doctor Mohamad Mohty is Professor of Haematology, and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. He. Over the past 25 years or so, Professor Mohty, an active member of the EBMT, has always been a key figure of the EBMT and in the stem cell transplant and cellular therapy field. He has published over 600 peer-reviewed articles internationally and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognized decorations.
MD, PhD
PhD
Robert R. Jenq, M.D., is director of the City of Hope® Microbiome Program and a clinical professor in the Department of Hematology and Hematopoietic Cell Transplantation. With more than 20 years’ experience as a physician-scholar with expertise in fields such as genomics, bone marrow and stem cell transplantation, Dr. Jenq is committed to bringing leading-edge translational research from the lab to cancer patients’ bedsides.
Dr. Peled is a medical oncologist at the Memorial Sloan Kettering Cancer Center. Dr Peled specializes in bone marrow transplantation for blood cancers including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.
He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.
His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.
MD, PhD
Professor of Medicine, Immunology and Dermatology at University of Pittsburgh School of Medicine, Pr. Zarour is a Cancer Immunologist with a long-lasting interest in cancer immunotherapies, cancer vaccines and human T cell immunology. His research focuses on immunotherapies of melanoma, T cell responses to melanoma antigens and on the mechanisms of melanoma-induced T cell dysfunction. He has made seminal contributions in the field of human cancer immunology, identifying multiple novel tumor antigen-specific CD4 epitopes, and determining the role of the novel inhibitory receptor pathways Tim-3 and TIGIT in impeding T cell responses to melanoma. Most recently, he has initiated translational studies evaluating the role of the gut microbiome in regulating clinical responses to PD-1 blockade in melanoma, including a first-in-human clinical trial to evaluate the safety and efficacy of fecal microbiota transplant (FMT) obtained from long-term PD-1 responder patients and pembrolizumab in PD-1 refractory melanoma patients. As a co-leader of the of the Cancer Immunology and Immunotherapy Program (CIIP), he will contribute to its mission, and together with basic and clinical investigators, foster the translation of novel laboratory findings into novel immunotherapy of cancers.
Co-Leader of the Melanoma and Skin Cancer SPORE
Co-Leader Cancer Immunology and Immunotherapy Program
